<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><front><journal-meta><journal-id journal-id-type="nlm-ta">Cell Transplant</journal-id><journal-id journal-id-type="iso-abbrev">Cell Transplant</journal-id><journal-id journal-id-type="pmc-domain-id">3327</journal-id><journal-id journal-id-type="pmc-domain">cll</journal-id><journal-id journal-id-type="publisher-id">CLL</journal-id><journal-title-group><journal-title>Cell Transplantation</journal-title></journal-title-group><issn pub-type="ppub">0963-6897</issn><issn pub-type="epub">1555-3892</issn><publisher><publisher-name>SAGE Publications</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC7444217</article-id><article-id pub-id-type="pmcid-ver">PMC7444217.1</article-id><article-id pub-id-type="pmcaid">7444217</article-id><article-id pub-id-type="pmcaiid">7444217</article-id><article-id pub-id-type="pmid">32495641</article-id><article-id pub-id-type="doi">10.1177/0963689720912925</article-id><article-id pub-id-type="publisher-id">10.1177_0963689720912925</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>A Limited Sampling Strategy for Therapeutic Drug Monitoring of
Mycophenolate Mofetil for Prophylaxis of Acute Graft-Versus-Host Disease in
Allogeneic Stem Cell Transplantation</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-6348-6667</contrib-id><name name-style="western"><surname>Gota</surname><given-names initials="V">Vikram</given-names></name><xref ref-type="aff" rid="aff1-0963689720912925">1</xref><xref ref-type="aff" rid="aff2-0963689720912925">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Purohit</surname><given-names initials="V">Vaitashi</given-names></name><xref ref-type="aff" rid="aff1-0963689720912925">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Gurjar</surname><given-names initials="M">Murari</given-names></name><xref ref-type="aff" rid="aff1-0963689720912925">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Nayak</surname><given-names initials="L">Lingaraj</given-names></name><xref ref-type="aff" rid="aff2-0963689720912925">2</xref><xref ref-type="aff" rid="aff3-0963689720912925">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Punatar</surname><given-names initials="S">Sachin</given-names></name><xref ref-type="aff" rid="aff2-0963689720912925">2</xref><xref ref-type="aff" rid="aff3-0963689720912925">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Gokarn</surname><given-names initials="A">Anant</given-names></name><xref ref-type="aff" rid="aff2-0963689720912925">2</xref><xref ref-type="aff" rid="aff3-0963689720912925">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Bonda</surname><given-names initials="A">Avinash</given-names></name><xref ref-type="aff" rid="aff2-0963689720912925">2</xref><xref ref-type="aff" rid="aff3-0963689720912925">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Bagal</surname><given-names initials="B">Bhausaheb</given-names></name><xref ref-type="aff" rid="aff2-0963689720912925">2</xref><xref ref-type="aff" rid="aff3-0963689720912925">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Vora</surname><given-names initials="CS">Chakor Sunil</given-names></name><xref ref-type="aff" rid="aff2-0963689720912925">2</xref><xref ref-type="aff" rid="aff3-0963689720912925">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Patil</surname><given-names initials="A">Anand</given-names></name><xref ref-type="aff" rid="aff1-0963689720912925">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Nookala</surname><given-names initials="M">Manjunath</given-names></name><xref ref-type="aff" rid="aff1-0963689720912925">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Khattry</surname><given-names initials="N">Navin</given-names></name><xref ref-type="aff" rid="aff2-0963689720912925">2</xref><xref ref-type="aff" rid="aff3-0963689720912925">3</xref><xref ref-type="corresp" rid="corresp1-0963689720912925"/></contrib></contrib-group><aff id="aff1-0963689720912925">
<label>1</label>Department of Clinical Pharmacology, Advanced Centre for Treatment,
Research and Education in Cancer (ACTREC), Tata Memorial Centre, Kharghar, Navi
Mumbai, Maharashtra, India</aff><aff id="aff2-0963689720912925">
<label>2</label>Homi Bhabha National Institute, Mumbai, Maharastra, India</aff><aff id="aff3-0963689720912925">
<label>3</label>Bone Marrow Transplant Unit, Advanced Centre for Treatment, Research
and Education in Cancer (ACTREC), Tata Memorial Centre, Kharghar, Navi Mumbai,
Maharashtra, India</aff><author-notes><corresp id="corresp1-0963689720912925">Navin Khattry, Bone Marrow Transplant Unit,
Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), Tata
Memorial Centre, Kharghar, Navi Mumbai, Maharashtra 410210, India. Email:
<email>nkhattry@gmail.com</email></corresp></author-notes><pub-date pub-type="epub"><day>4</day><month>6</month><year>2020</year></pub-date><pub-date pub-type="collection"><season>Jan-Dec</season><year>2020</year></pub-date><volume>29</volume><issue-id pub-id-type="pmc-issue-id">363830</issue-id><elocation-id>0963689720912925</elocation-id><history><date date-type="received"><day>28</day><month>2</month><year>2019</year></date><date date-type="rev-recd"><day>10</day><month>2</month><year>2020</year></date><date date-type="accepted"><day>19</day><month>2</month><year>2020</year></date></history><pub-history><event event-type="pmc-release"><date><day>04</day><month>06</month><year>2020</year></date></event><event event-type="pmc-live"><date><day>09</day><month>09</month><year>2020</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2020-09-10 00:39:18.913"><day>10</day><month>09</month><year>2020</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2020</copyright-statement><copyright-year>2020</copyright-year><copyright-holder content-type="sage">SAGE Publications Inc, unless otherwise noted.
Manuscript content on this site is licensed under Creative Commons
Licenses</copyright-holder><license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="creative-commons" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/"><license-p>This article is distributed under the terms of the Creative Commons
Attribution-NonCommercial 4.0 License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">https://creativecommons.org/licenses/by-nc/4.0/</ext-link>) which
permits non-commercial use, reproduction and distribution of the work
without further permission provided the original work is attributed as
specified on the SAGE and Open Access pages (<ext-link ext-link-type="uri" xlink:href="https://us.sagepub.com/en-us/nam/open-access-at-sage">https://us.sagepub.com/en-us/nam/open-access-at-sage</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="10.1177_0963689720912925.pdf"/><abstract><p>A universally accepted strategy for therapeutic drug monitoring (TDM) of
mycophenolate mofetil (MMF) in the prevention of acute graft-versus-host disease
(aGVHD) in allogenic hematopoietic stem cell transplantation (alloHSCT) does not
exist. We explored the feasibility of developing a limited sampling strategy
(LSS) for TDM of MMF in this setting. Patients undergoing alloHSCT received
standard MMF-cyclosporine prophylaxis, with MMF administered twice daily (BD)
for matched transplant recipients or thrice daily (TID) in haploidentical
transplantation. Intensive blood sampling was carried out on day 7 and area
under the concentration&#8211;time curve (AUC) of mycophenolic acid (MPA), the active
metabolite, was estimated using noncompartmental analysis. The ability of MPA
exposure defined by AUC<sub>0-12</sub> to discriminate between responders
(patients who did not develop GVHD) and nonresponders (patients who developed
GVHD) was determined by receiver operating characteristic curve analysis.
Patients were divided into training and validation sets within BD and TID
groups. Mathematical equations were developed from the training set to predict
AUC<sub>0-12</sub> from an abbreviated AUC involving a limited number of
sampling points. The equations were validated in the validation set by comparing
the MPA AUC<sub>0-12</sub> predicted from LSS with the observed
AUC<sub>0-12</sub>. It was observed that patients with AUC<sub>0-12</sub>
&#8804;18.99 mg*h/L had a higher risk of developing aGVHD [odds ratio (OR) = 2.63
(1.17 to 5.87), <italic toggle="yes">P</italic> = 0.06]. The benefit was more in matched
transplant recipients [OR = 3.5 (1.30 to 9.49), <italic toggle="yes">P</italic> = 0.05] as
compared to haploindentical transplant [OR = 2.8 (0.49 to 15.91),
<italic toggle="yes">P</italic> = NS]. Using the mathematical equations, the observed
AUC<sub>0-12</sub> was predicted with 92.31% accuracy in the BD subset and
100% accuracy in the TID subset for a combined accuracy of 94.76%. A set of just
three samples that constituted the abbreviated AUC<sub>1-4</sub> was used to
develop the predictive models. The LSS could be employed for the therapeutic
monitoring of MMF particularly in patients undergoing matched hematopoietic stem
cell transplantation.</p></abstract><kwd-group><kwd>therapeutic drug monitoring</kwd><kwd>graft-versus-host disease</kwd><kwd>hematopoietic stem cell transplantation</kwd><kwd>mycophenolate mofetil</kwd></kwd-group><funding-group><award-group id="award1-0963689720912925"><funding-source id="funding1-0963689720912925"><institution-wrap><institution>Advanced Centre for Treatment, Research and Education in
Cancer</institution><institution-id institution-id-type="FundRef">https://doi.org/10.13039/501100007179</institution-id></institution-wrap></funding-source><award-id rid="funding1-0963689720912925">Intramural</award-id></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>January-December 2020</meta-value></custom-meta><custom-meta><meta-name>typesetter</meta-name><meta-value>ts3</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="section1-0963689720912925"><title>Introduction</title><p>Allogeneic hematopoietic stem cell transplantation (alloHSCT) is performed with
increasing frequency in an effort to cure patients with malignant hematological
diseases but the therapeutic benefits are limited by the morbidity and mortality
associated with graft-versus-host disease (GVHD)<sup><xref rid="bibr1-0963689720912925" ref-type="bibr">1</xref></sup>. Acute GVHD (aGVHD) is defined as any GVHD developing within 100 days of bone
marrow transplantation. Current agents for the prevention and treatment of GVHD are
partially effective and often result in significant toxicities. Mycophenolate
mofetil (MMF), the prodrug of mycophenolic acid (MPA), is a widely used
immunosuppressant to prevent graft rejection in solid organ transplantation. Because
of its better tolerability, MMF has also been introduced as a replacement for
methotrexate in GVHD prophylaxis<sup><xref rid="bibr2-0963689720912925" ref-type="bibr">2</xref></sup>.</p><p>Clinical experience in solid organ allograft recipients has shown that MMF has the
ability to decrease the incidence and severity of acute rejection episodes<sup><xref rid="bibr3-0963689720912925" ref-type="bibr">3</xref><xref rid="bibr4-0963689720912925" ref-type="bibr"/><xref rid="bibr5-0963689720912925" ref-type="bibr"/>&#8211;<xref rid="bibr6-0963689720912925" ref-type="bibr">6</xref></sup>. The safety profile of MMF in this setting is acceptable and does not overlap
with the significant toxicities of commonly used immunosuppressant agents.
Combination regimens that include MMF have shown that it permits a reduction in dose
of cyclosporine, tacrolimus, or corticosteroid without increasing the chances of
acute rejections<sup><xref rid="bibr7-0963689720912925" ref-type="bibr">7</xref><xref rid="bibr8-0963689720912925" ref-type="bibr"/>&#8211;<xref rid="bibr9-0963689720912925" ref-type="bibr">9</xref></sup>. The systemic exposure of MPA is unpredictable and wide variations in
pharmacokinetics have been reported<sup><xref rid="bibr2-0963689720912925" ref-type="bibr">2</xref>,<xref rid="bibr10-0963689720912925" ref-type="bibr">10</xref><xref rid="bibr11-0963689720912925" ref-type="bibr"/><xref rid="bibr12-0963689720912925" ref-type="bibr"/>&#8211;<xref rid="bibr13-0963689720912925" ref-type="bibr">13</xref></sup>. Thus, therapeutic drug monitoring (TDM) of MMF is routinely practiced in
solid organ transplants to target a specified area under the concentration&#8211;time
curve (AUC) based on exposure&#8211;effect relationship. TDM using limited sampling
strategies (LSSs) has been shown to allow good prediction of the full
area-under-the-curve and improve clinical outcomes<sup><xref rid="bibr14-0963689720912925" ref-type="bibr">14</xref></sup>.</p><p>Similarly, individualized dosing using TDM approaches could be useful for optimizing
MMF treatment in alloHSCT as well<sup><xref rid="bibr15-0963689720912925" ref-type="bibr">15</xref></sup>. However, few such reports are available, and hence, no consensus on TDM
strategy exists in this setting<sup><xref rid="bibr16-0963689720912925" ref-type="bibr">16</xref></sup>. There are limited data showing effectiveness of MMF in alloHSCT, much less
about the disposition of the drug and its exposure&#8211;response relationship in the
context of GVHD prophylaxis<sup><xref rid="bibr17-0963689720912925" ref-type="bibr">17</xref></sup>. Several studies in the past have not been successful in developing a
strategy for TDM of MMF in alloHSCT<sup><xref rid="bibr18-0963689720912925" ref-type="bibr">18</xref>,<xref rid="bibr19-0963689720912925" ref-type="bibr">19</xref></sup>.</p><p>A good TDM strategy should have few but informative set of sampling to make it
effective, convenient, and economical. Obtaining multiple samples for TDM to
calculate total exposure (AUC) will be expensive, cumbersome, and often not
feasible. The present study was aimed at developing a TDM strategy for MMF in
alloHSCT using a limited sampling approach.</p></sec><sec sec-type="materials|methods" id="section2-0963689720912925"><title>Materials and Methods</title><sec id="section3-0963689720912925"><title>Patients and Settings</title><p>A clinical pharmacokinetic (PK) study was performed to assess the feasibility of
TDM of MMF in alloHSCT setting. Forty eight patients aged &#8805;18 years undergoing
alloHSCT for hematological malignancies at our center were enrolled into the
study from July 2012 to June 2015. MMF was administered at twice daily (BD) or
thrice daily (TID) frequency along with cyclosporine (CsA), which is standard
institutional practice for the prophylaxis of GVHD. Patients receiving BD
regimen were administered 600 mg/m2 PO dose of MMF up to a maximum of 1,500 mg
per dose and those receiving TID regimen were administered a dose of 15 mg/kg PO
up to a maximum of 1,000 mg per dose. Conditioning regimens used were either
full intensity such as cyclophosphamide with 12 to 14.4 Gy TBI or reduced
intensity such as fludarabine with either melphalan or treosulfan or
cyclophosphamide with or without 2 Gy TBI.</p><p>Those with matched related or unrelated donors received CsA-MMF prophylaxis from
day &#8722;1. All patients who underwent unrelated donor transplants and some patients
with 8/10 or 9/10 matched related transplant also received 1 or 2 doses of 2.5
mg/kg of rabbit antithymoglobulin (rATG) with conditioning regimen. Alemtuzumab,
wherever indicated for related donor transplantation, was administered at a dose
of 10 mg for 3 days with the conditioning regimen. MMF was stopped on day +30 if
there was no evidence of GVHD. In these patients, MMF was exclusively used at a
dose of 600 mg/m2 BD to a maximum of 1,500 mg per dose. These patients received
CsA at a dose of 1.5 mg/kg intravenous BD from day &#8722;1. CsA tapering was started
from day +60 to day +90 and stopped by day +150 to day +180 if there was no
evidence of GVHD.</p><p>Patients who underwent haploidentical transplant received CsA-MMF from day +5
till day +35. MMF was administered TID in these patients. All these patients
also received post-transplant cyclophosphamide (PTCY) at a dose of 50 mg/kg
daily on day +3 and day +4.</p></sec><sec id="section4-0963689720912925"><title>PK Sampling</title><p>Intensive blood sampling (3 ml each in EDTA tubes) was performed on day 7 of MMF
treatment. Samples were collected predose (0 h) and 0.5, 1, 2, 4, 6, 8, and 12 h
post dose in BD and 0, 0.5, 1, 2, 4, 6, and 8 h post dose in TID regimen,
respectively.</p></sec><sec id="section5-0963689720912925"><title>Bioanalysis</title><p>Blood samples were centrifuged for 10 min at 3,000 rpm. Plasma was separated and
stored at &#8722;20&#176;C. Samples were analyzed within 6 months of collection for plasma
MPA levels using a validated high-performance liquid chromatography assay.</p></sec><sec id="section6-0963689720912925"><title>Estimation of MPA Exposure</title><p>AUC was estimated using linear trapezoid rule. The ability of MPA exposure
defined by AUC<sub>0-12</sub> to discriminate between responders and
nonresponders was determined by receiver operating characteristic (ROC)
analysis. In the BD regimen, AUC<sub>0-12</sub> was estimated directly from PK
samples collected over the 12-h period. In TID regimen, AUC<sub>0-12</sub> was
calculated from AUC<sub>0-8</sub> using a multiplication factor of 1.5 as a
simple approximation of the measure of exposure over 12 h.</p></sec><sec id="section7-0963689720912925"><title>Phase 1 (Feasibility Study, <italic toggle="yes">N</italic> = 20)</title><p>During this phase blood samples were collected at specified time points. Plasma
concentration&#8211;time curve was plotted for MPA and AUC<sub>0-12</sub> was
estimated for all patients using noncompartmental analysis. A target
AUC<sub>0-12</sub> of 30 mg h/l was set based on monitoring threshold
observed in solid organ transplant. A strategy for TDM was deemed necessary if
more than 6 out of 20 patients (30%) failed to achieve the target AUC.</p></sec><sec id="section8-0963689720912925"><title>Phase 2 (Predictive Models to Calculate AUC<sub>0-12</sub> from Abbreviated
AUCs)</title><p>Additional 28 patients (for a total of 48 subjects) were enrolled for development
and validation of a predictive model using limited sampling approach. The total
pool consisted of 2 subsets of patients; 33 who were administered MMF BD and 15
who received the TID regimen. The least number of samples (LSS) from which
AUC<sub>0-12</sub> could be determined accurately was determined by
Pearson&#8217;s correlation.<list list-type="roman-upper"><list-item><p>For patients who were dosed BD: Predictive AUC for first 20 patients
using concentrations at only 3 time points of all possible
combination that is AUC<sub>0.5-2</sub>, AUC<sub>1-4</sub>, and
AUC<sub>2-6</sub> was calculated and regressed against observed
oral AUC<sub>0-12</sub> and the equation with highest correlation
coefficient (<italic toggle="yes">r</italic>2) was used to estimate
AUC<sub>0-12</sub> for the remaining 13 patients. To validate
the model, the MPA AUC derived from limited sampling model was
compared with the MPA observed AUC<sub>0-12</sub>. The accuracy of
the model was determined by its ability to predict AUC falling into
&#8220;inadequate exposure&#8221; and &#8220;adequate exposure&#8221; as determined by the
ROC analysis.</p></list-item><list-item><p>For patients who were dosed TID: Similarly, the first eight patients
were employed for development of the predictive model using the same
limited sampling time points as above. The predictive model was
validated in the remaining patients against the AUC threshold
determined in the ROC analysis.</p></list-item></list>
</p></sec><sec id="section9-0963689720912925"><title>Efficacy Assessment</title><p>A pooled analysis of training and validation sets was carried out to determine
the efficacy of TDM strategy. Odds ratio with one-sided 90% confidence interval
was calculated for the risk of developing aGVHD at exposures below the threshold
AUC<sub>0-12</sub> determined from ROC analysis. <italic toggle="yes">P</italic> value
less than 0.10 was considered statistically significant.</p></sec><sec id="section10-0963689720912925"><title>Statistical Analysis</title><p>All statistical analyses were performed using GraphPad Prism, version 6
(GraphPad, San Diego, CA, USA). AUC was also estimated using GraphPad Prism,
version 6 software.</p></sec></sec><sec sec-type="results" id="section11-0963689720912925"><title>Results</title><p>Forty-eight patients were enrolled in the study, of which 47 were evaluable for drug
exposure. One of the patients who underwent haploidentical transplant was not
included in the final analysis since the blood samples could not be analyzed for MPA
levels due to hemolysis. Conditioning regimen consisted of fludarabine-based reduced
intensity conditioning in 45 cases and myeloablative conditioning with
cyclophosphamide plus total body irradiation in two cases. GVHD prophylaxis
consisted of CsA and MMF (CSA-MMF) (<italic toggle="yes">N</italic> = 25), CSA-MMF-Alemtuzumab
(<italic toggle="yes">N</italic> = 2), CSA-MMF-rATG (<italic toggle="yes">N</italic> = 6), and
CSA-MMF-PTCY (<italic toggle="yes">N</italic> = 14). The flow chart of the study is shown in
<xref ref-type="fig" rid="fig1-0963689720912925">Figure 1</xref>. Patient
characteristics are summarized in <xref rid="table1-0963689720912925" ref-type="table">Table 1</xref>.</p><fig id="fig1-0963689720912925" orientation="portrait" position="float"><label>Fig. 1.</label><caption><p>Study flow chart.</p><p>AUC: area under the concentration&#8211;time curve; BD: twice daily; GvHD:
graft-versus-host disease; TDS: thrice daily; ROC: receiver operating
characteristic.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="10.1177_0963689720912925-fig1.jpg"/></fig><table-wrap id="table1-0963689720912925" orientation="portrait" position="float"><label>Table 1.</label><caption><p>Patient Demographics.</p></caption><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="10.1177_0963689720912925-table1.jpg"/><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1">Characteristics</th><th colspan="2" rowspan="1">Median, range<break/>(<italic toggle="yes">N</italic> =
47&#8212;evaluable)</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Sex</td><td align="center" colspan="2" rowspan="1">Male: 35, Female: 12</td></tr><tr><td rowspan="1" colspan="1">Age (years)</td><td align="center" colspan="2" rowspan="1">35, 24&#8211;42</td></tr><tr><td rowspan="1" colspan="1">Weight (kg)</td><td align="center" colspan="2" rowspan="1">64, 56&#8211;75</td></tr><tr><td rowspan="1" colspan="1">Height (cm)</td><td align="center" colspan="2" rowspan="1">165, 156&#8211;170</td></tr><tr><td rowspan="1" colspan="1">Diagnosis</td><td align="center" colspan="2" rowspan="1">AML: 22, ALL: 7, MDS: 5, HL: 3, CML:
6, AA: 1, PMF: 3</td></tr><tr><td rowspan="1" colspan="1">Type of transplant</td><td align="center" colspan="2" rowspan="1">MRT: 29, MUD: 4, HT: 14</td></tr><tr><td rowspan="1" colspan="1">ALT (U/l)</td><td align="center" colspan="2" rowspan="1">33, 29&#8211;43</td></tr><tr><td rowspan="1" colspan="1">AST (U/l)</td><td align="center" colspan="2" rowspan="1">17, 14&#8211;24</td></tr><tr><td rowspan="1" colspan="1">Total bilirubin (mg/dl)</td><td align="center" colspan="2" rowspan="1">0.75, 0.29&#8211;3.0</td></tr><tr><td rowspan="1" colspan="1">Serum creatinine (mg/dl)</td><td align="center" colspan="2" rowspan="1">0.73, 0.28&#8211;1.25</td></tr><tr><td rowspan="2" colspan="1">Actual dose of MMF (median, IQR)</td><td rowspan="1" colspan="1">BD (<italic toggle="yes">n</italic> = 33)</td><td rowspan="1" colspan="1">1,000 (1,000&#8211;1,000)</td></tr><tr><td rowspan="1" colspan="1">TID (<italic toggle="yes">n</italic> = 14)</td><td rowspan="1" colspan="1">500 (500&#8211;500)</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="table-fn1-0963689720912925"><p>AA: aplastic anemia; ALL: acute lymphoblastic leukemia; ALT: alanine
aminotransferase; AML: acute myeloid leukemia; AST: aspartate
aminotransferase; BD: twice daily; CML: chronic myeloid leukemia; HL:
Hodgkin lymphoma; HT: haploidentical transplant; IQR: interquartile
range; MDS: myelodysplastic syndrome; MMF: mycophenolate mofetil; MRT:
matched related transplant; MUD: matched unrelated transplant; PMF:
primary myelofibrosis; TID: three times a day.</p></fn></table-wrap-foot></table-wrap><sec id="section12-0963689720912925"><title>Feasibility Study</title><p>The average concentration&#8211;time profile of MPA for 20 patients enrolled in the
feasibility study is shown in <xref ref-type="fig" rid="fig2-0963689720912925">Figure 2</xref>. The interpatient coefficient of variation of MPA
AUC<sub>0-12</sub> was found to be 37.18%. The AUC recommended for solid
organ transplant is &gt;30 mg*h/L. Fifteen out of 20 patients did not achieve
the recommended AUC. Thus, TDM may have a role in optimizing MMF dose in
patients undergoing alloHSCT.</p><fig id="fig2-0963689720912925" orientation="portrait" position="float"><label>Fig. 2.</label><caption><p>Concentration&#8211;time profile of MPA. Data are shown as mean &#177; SD.</p><p>MPA: mycophenolic acid.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="10.1177_0963689720912925-fig2.jpg"/></fig></sec><sec id="section13-0963689720912925"><title>Relation Between Acute GVHD and MPA Exposure</title><p>The average MPA exposure was 23.15 &#177; 12.18 mg h/l. ROC analysis showed that an
AUC of 18.99 mg*h/L could discriminate between responders (no GVHD) and
nonresponders (GVHD) with highest sensitivity and specificity. Patients with
AUC<sub>0-12</sub> &#8804;18.99 mg*h/L were at higher risk of developing aGVHD
compared to those who achieved higher exposure [odds ratio = 2.63 (1.17 to
5.87), <italic toggle="yes">P</italic> = 0.06] (<xref ref-type="fig" rid="fig3-0963689720912925">Figure 3</xref>). The odds ratio in patients who
underwent matched donor transplantation (<italic toggle="yes">N</italic> = 33) was 3.5 (1.30
to 9.49), <italic toggle="yes">P</italic> = 0.05. On the other hand, the odds ratio for
haploidentical transplant recipients at the same AUC cut-off was 2.8 (0.490 to
15.91), <italic toggle="yes">P</italic> = NS.</p><fig id="fig3-0963689720912925" orientation="portrait" position="float"><label>Fig. 3.</label><caption><p>Relation between GVHD and MPA exposure. MPA exposure is shown as a
categorical variable at the AUC<sub>0-12</sub> cut-off found to have the
optimal sensitivity and specificity to discriminate between occurrence
and non-occurrence of GVHD. The odds for the occurrence of GVHD at lower
exposure was found to be 2.63 (1.17 to 5.87), <italic toggle="yes">P</italic> =
0.06.</p><p>AUC: area under the concentration&#8211;time curve; GVHD: graft-versus-host
disease; MPA: mycophenolic acid.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="10.1177_0963689720912925-fig3.jpg"/></fig></sec><sec id="section14-0963689720912925"><title>Development and Validation of LSS</title><sec id="section15-0963689720912925"><title>I) BD dosing</title><p>The minimum number of sampling time points that can accurately estimate the
total AUC<sub>0-12</sub> was modeled in 20 patients. Three time points,
i.e., AUC<sub>1-4</sub> had highest correlation with AUC<sub>0-12</sub>
(<italic toggle="yes">r</italic>
<sup>2</sup> = 0.65) compared to other limited sample AUCs including
AUC<sub>0.5-2</sub> (<italic toggle="yes">r</italic>
<sup>2</sup> = 0.38) and AUC<sub>2-6</sub> (<italic toggle="yes">r</italic>
<sup>2</sup> = 0.51)<sub>.</sub> AUC<sub>0-12</sub> was predicted from
AUC<sub>1-4</sub> using the equation AUC<sub>0-12</sub> = (1.2039 *
AUC<sub>1-4</sub>)+8.9727 (<xref rid="table2-0963689720912925" ref-type="table">Table 2</xref>). This model was further
validated in 13 patients. Observed and predicted values of MPA were in
agreement in 12 out of 13 patients at the AUC cutoff of 18.99 mg*h/L giving
the model a predictive accuracy of 92.31%.</p><table-wrap id="table2-0963689720912925" orientation="portrait" position="float"><label>Table 2.</label><caption><p>Correlation Between Various Abbreviated AUCs and Total MPA Exposure
in Twice-Daily and Thrice-Daily Regimen.</p></caption><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="10.1177_0963689720912925-table2.jpg"/><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1">Abbreviated AUCs</th><th rowspan="1" colspan="1">Coefficient of determination (<italic toggle="yes">r</italic>
<sup>2</sup>) between abbreviated AUCs and
AUC<sub>0-12</sub> (<italic toggle="yes">N</italic> = 20)</th><th rowspan="1" colspan="1">Coefficient of determination (<italic toggle="yes">r</italic>
<sup>2</sup>) between abbreviated AUCs and
AUC<sub>0-8</sub> (<italic toggle="yes">N</italic> = 8)</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">AUC<sub>1-4</sub> (sampling time 1, 2, and 4 h)</td><td rowspan="1" colspan="1">0.65</td><td rowspan="1" colspan="1">0.69</td></tr><tr><td rowspan="1" colspan="1">AUC<sub>0.5-2</sub> (sampling time 0.5, 1, and 2 h)</td><td rowspan="1" colspan="1">0.38</td><td rowspan="1" colspan="1">0.24</td></tr><tr><td rowspan="1" colspan="1">AUC<sub>2-6</sub> (sampling time 2, 4, and 6 h)</td><td rowspan="1" colspan="1">0.51</td><td rowspan="1" colspan="1">0.08</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="table-fn2-0963689720912925"><p>AUC: area under the concentration&#8211;time curve; MPA: mycophenolic
acid.</p></fn></table-wrap-foot></table-wrap></sec><sec id="section16-0963689720912925"><title>II) TID dosing</title><p>The minimum number of sampling time points that can accurately estimate the
total AUC<sub>0-8</sub> was modeled in eight patients. Once again, the same
three time points, i.e., AUC<sub>1-4</sub> had highest correlation with
AUC<sub>0-8</sub> (<italic toggle="yes">r</italic>
<sup>2</sup> = 0.69) compared to other limited sample AUCs including
AUC<sub>0.5-2</sub> (<italic toggle="yes">r</italic>
<sup>2</sup> = 0.24) and AUC<sub>2-6</sub> (<italic toggle="yes">r</italic>
<sup>2</sup> = 0.08) (<xref rid="table2-0963689720912925" ref-type="table">Table 2</xref>)<sub>.</sub> AUC<sub>0-8</sub> was predicted from
AUC<sub>1-4</sub> using the equation AUC<sub>0-8</sub> = (1.5164 *
AUC<sub>1-4</sub>)+2.0295. The model was further validated in six
patients. Observed and predicted values of MPA were in agreement in all six
patients at the AUC cutoff of 18.99 mg*h/L giving the model a predictive
accuracy of 100%.</p><p>In all, 17 out of 47 patients (36.2%) developed aGVHD, 12 in the BD regimen,
and 5 in the TID regimen. The incidence of aGVHD was 36.4% in the BD regimen
and 35.7% in the TID regimen (<italic toggle="yes">P</italic> = 0.96). The average
AUC<sub>0-12</sub> was 22.89 &#177; 10.44 (mean &#177; SD) in the BD regimen and
23.76 &#177; 15.99 (mean &#177; SD) in the TID regimen (<italic toggle="yes">P</italic> = 0.83).
The predictive ability of combined BD and TID models is shown in <xref ref-type="fig" rid="fig4-0963689720912925">Figure 4</xref>. The model
predicted accurately in 18 out of 19 cases giving it an accuracy of
94.74%.</p><fig id="fig4-0963689720912925" orientation="portrait" position="float"><label>Fig. 4.</label><caption><p>Scatter plot showing accuracy of prediction of AUC<sub>0-12</sub>
from limited sampling timepoints for combined twice- and
thrice-daily regimen of MMF (<italic toggle="yes">N</italic> = 19). The
prediction was 94.74% accurate at the AUC<sub>0-12</sub> cutoff of
18.99 mg*h/L.</p><p>AUC: area under the concentration&#8211;time curve; MMF: mycophenolate
mofetil.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="10.1177_0963689720912925-fig4.jpg"/></fig></sec></sec></sec><sec sec-type="discussion" id="section17-0963689720912925"><title>Discussion</title><p>MMF has been successfully introduced into alloHSCT for prophylaxis against acute
GVHD. Although not officially licensed<sup><xref rid="bibr20-0963689720912925" ref-type="bibr">20</xref>,<xref rid="bibr21-0963689720912925" ref-type="bibr">21</xref></sup>, many transplant physicians use it for GVHD prophylaxis in the alloHSCT
setting because of its synergistic action with CsA<sup><xref rid="bibr22-0963689720912925" ref-type="bibr">22</xref>,<xref rid="bibr23-0963689720912925" ref-type="bibr">23</xref></sup>. However, its reportedly high interindividual variability in pharmacokinetics
leads to toxicity or lack of therapeutic effect at standard doses<sup><xref rid="bibr24-0963689720912925" ref-type="bibr">24</xref><xref rid="bibr25-0963689720912925" ref-type="bibr"/>&#8211;<xref rid="bibr26-0963689720912925" ref-type="bibr">26</xref></sup>. This makes MMF an ideal candidate for TDM-based dosing.</p><p>A high variability in MPA pharmacokinetics was observed in our patients as well. Our
study shows that an AUC<sub>0-12</sub> of &#8764;19 mg h/l is required for adequate GVHD
prophylaxis, whereas the reported threshold in solid organ transplant is 30 mg h/l<sup><xref rid="bibr27-0963689720912925" ref-type="bibr">27</xref></sup>. In general, we observed lower exposures in our patients compared to solid
transplant setting possibly due to concomitant administration with CSA. CSA reduces
the enterohepatic recirculation of MPA resulting in lower total exposure of MPA<sup><xref rid="bibr28-0963689720912925" ref-type="bibr">28</xref>,<xref rid="bibr29-0963689720912925" ref-type="bibr">29</xref></sup>. Even in recipients of kidney transplant, MPA exposure was shown to be
significantly lower in patients who received concomitant CSA as compared to those
who received tacrolimus. Calcineurin inhibitors influenced the urinary excretion of
MPA in kidney transplant recipients by interfering with its renal tubular secretion<sup><xref rid="bibr30-0963689720912925" ref-type="bibr">30</xref></sup>. Previously, the relationship between AUC0-12 of unbound MPA of less than 0.3
mg h/l was shown to be associated with significantly higher incidence of aGVHD
following alloHSCT<sup><xref rid="bibr31-0963689720912925" ref-type="bibr">31</xref></sup>. Considering MPA is approximately 98% protein bound, this translates to a
total MPA AUC<sub>0-12</sub> of approximately 15 mg h/l. The corresponding threshold
in solid organ transplantation for the prevention of organ rejection is 30 mg h/l. A
similar study in lung and heart transplant also reported lower MMF exposure when
administered concomitantly with CSA as compared to tacrolimus<sup><xref rid="bibr32-0963689720912925" ref-type="bibr">32</xref></sup>.</p><p>A few studies have demonstrated the utility of TDM of MMF in alloHSCT. Windreich and
colleagues demonstrated the utility of LSS for the TDM of MMF in pediatric patients
undergoing HSCT. In their study, they set a lower threshold of 40 mg h/l as the
target AUC<sub>0-24</sub> considering the fact that MPA exposure in HSCT is 30% to
50% of that achieved for similar doses in kidney transplantation. Using this
strategy they achieved excellent engraftment and low rates of acute GVHD<sup><xref rid="bibr33-0963689720912925" ref-type="bibr">33</xref></sup>. In a retrospective study of 36 patients who underwent unrelated alloHSCT,
AUC<sub>0-24</sub> correlated with GVHD incidence and overall survival<sup><xref rid="bibr29-0963689720912925" ref-type="bibr">29</xref></sup>. Jacobson P et al demonstrated the utility of monitoring exposure
(AUC<sub>0-6</sub> or AUC<sub>0-12</sub>) of unbound MPA for effective
prophylaxis of aGVHD in alloHSCT<sup><xref rid="bibr31-0963689720912925" ref-type="bibr">31</xref></sup>. In spite of these efforts, there is no clear consensus on the preferred MPA
PK monitoring parameters and target range in alloHSCT recipients<sup><xref rid="bibr34-0963689720912925" ref-type="bibr">34</xref></sup>. Our study has demonstrated that an MPA AUC of &#8764;19 mg h/l is required for
adequate aGVHD prophylaxis, and that the AUC can be estimated with reasonable
accuracy from a LSS involving only three time points. Interestingly, patients who
underwent matched donor transplantation had a higher odds ratio as compared to
haploidentical transplant recipients who in addition to CsA-MMF also received PTCY.
Thus, the failure of prophylaxis was higher in matched transplant recipients if the
patients did not achieve the desired exposure, but it did not seem to matter so much
in the PTCY cohort with only two out of seven patients developing aGVHD at less than
optimal exposure. PTCY might offset the effects of low MPA exposure making MPA
levels irrelevant. Therefore, haploidentical transplant recipients are unlikely to
benefit from therapeutic monitoring of MMF. We could not make any conclusions in
patients receiving alemtuzumab or rATG due to a small number of patients subjected
to this regimen.</p><p>Limited sampling strategies are widely used in kidney transplantation. Most of the
TDM strategies for MMF in renal transplantation have been described in combination
with tacrolimus and very few with CsA. Most sampling strategies in kidney
transplantation use 3 or 4 time points over a 12-h dosing interval after oral administration<sup><xref rid="bibr35-0963689720912925" ref-type="bibr">35</xref>,<xref rid="bibr36-0963689720912925" ref-type="bibr">36</xref></sup>. In fact, sampling up to 3 to 6 h post dose has been shown to be reasonably
accurate for the prediction of total AUC<sup><xref rid="bibr37-0963689720912925" ref-type="bibr">37</xref>,<xref rid="bibr38-0963689720912925" ref-type="bibr">38</xref></sup>. Brooks et al and Willis et al examined the predictive performance previously
published LSS studies in prospective cohorts of patients<sup><xref rid="bibr37-0963689720912925" ref-type="bibr">37</xref>,<xref rid="bibr39-0963689720912925" ref-type="bibr">39</xref></sup>. A wide range of agreement was found when predicted AUCs were compared with
full AUCs (range: <italic toggle="yes">r</italic>
<sup>2</sup> = 0.16 to 0.91). In the study by Brooks et al, only 2 out of 19 models
had correlation of determination greater than 0.75. However, these equations also
used six to eight sampling time points over 8 h. Only two out of seven models having
three sampling time points had <italic toggle="yes">r</italic>
<sup>2</sup> greater than 0.65. In general, predictive models with more number of
samples fared better. The r2 in our study ranged from 0.65 (BD regimen) to 0.69 (TID
regimen). However, the accuracy of our models to predict the total AUC with respect
to threshold AUC was 92.31% and 100%, respectively. Thus, the correlation of
determination should be judged in the context of sensitivity and specificity of the
model. Also, fewer sampling time points make the TDM strategy financially viable and
acceptable to physicians and patients alike.</p><p>Previous studies in alloHSCT failed to show good correlation between total observed
AUC and AUC predicted from limited time points used in kidney transplant setting.
Again, we believe this could be due to concomitant administration of CSA in
alloHSCT, which interferes with the enterohepatic recirculation and renal tubular
secretion of MPA. Thus, there is a need to develop and utilize limited sampling
approaches specific to alloHSCT. The three-point sampling identified by us is unique
in that sense and hence generalizable to patients undergoing alloHSCT.</p><p>TDM strategies have to justify the costs involved. The three-point sampling can be
done for a total cost of less than 25 USD. While we did not carry out a detailed
pharmacoeconomic analysis, it is certainly going to be cost effective considering
the fact that more than one-third of our patients had exposure below the desired
cutoff.</p><p>The study had a few limitations. We did not measure free MPA and MPAG
(7-O-MPA-glucuronide) levels. Free MPA levels are known to correlate with the
toxicity of MMF<sup><xref rid="bibr14-0963689720912925" ref-type="bibr">14</xref>,<xref rid="bibr40-0963689720912925" ref-type="bibr">40</xref><xref rid="bibr41-0963689720912925" ref-type="bibr"/>&#8211;<xref rid="bibr42-0963689720912925" ref-type="bibr">42</xref></sup>. However, in the setting of alloHSCT with multiple coadministered drugs,
assessment of toxicity and attributing its causality to a given drug would have been
difficult. Moreover, this study was designed to develop a strategy for TDM of MMF
with respect to GVHD outcomes. Therefore, we did not attempt to measure free MPA
levels. Also, measurement of free levels is more expensive and technically
challenging and hence it is unlikely to translate into routine practice. MPAG, on
the other hand, is pharmacologically inactive. However, estimating its levels may
have shed light on the reasons for low MPA AUC observed in our study because CsA is
known to inhibit MRP2-mediated biliary secretion of MPAG and corresponding
enterohepatic recycling of MPA<sup><xref rid="bibr43-0963689720912925" ref-type="bibr">43</xref><xref rid="bibr44-0963689720912925" ref-type="bibr"/>&#8211;<xref rid="bibr45-0963689720912925" ref-type="bibr">45</xref></sup>. Secondly, the patient population was highly heterogeneous in terms of donor
sources, conditioning regimens, and GVHD prophylaxis regimens including the
frequency of administration of MMF. Establishing the relationship between MMF
exposure and the risk of aGVHD is very difficult in a small yet heterogeneous
sample. Also, we had patients who were treated with different MMF regimens, which
necessitated a conversion factor of 1.5 to be used on AUC<sub>0-8</sub> to obtain
AUC<sub>0-12</sub>. This conversion gives the average exposure of MPA over a
12-h duration. The rationale for the conversion factor is provided in supplemental
file S1.</p><p>Undoubtedly, the sample size in the training and validation set was relatively small.
In bone marrow transplantation, sample size is often limited by feasibility,
especially in single-center studies. We did not have a formal sample size
calculation, and the sample size was dictated by what was feasible in a reasonable
time span. Even in kidney transplant, studies evaluating limited sampling strategies
for TDM of MMF have typically had small sample size in the range of 20 to 40 patients<sup><xref rid="bibr36-0963689720912925" ref-type="bibr">36</xref>,<xref rid="bibr37-0963689720912925" ref-type="bibr">37</xref>,<xref rid="bibr46-0963689720912925" ref-type="bibr">46</xref></sup>. While TDM was found to benefit the matched transplant subset (MRT and MUD),
the overall odds ratio for the pooled analysis was somewhat lower, albeit
statistically significant, attributable largely to the haploidentical subset who do
not seem to derive benefit from TDM. Thus, future studies to validate these findings
should focus only on matched transplant recipients.</p><p>To conclude, we have demonstrated that MPA exposure determines the outcome of GVHD
prophylaxis, particularly in patients undergoing matched transplantation. The total
exposure can be predicted from limited number of samples with acceptable accuracy.
The findings are applicable to patients undergoing alloHSCT receiving CsA and MMF
for aGVHD prophylaxis, but not for other combinations of MMF. The proposed strategy
facilitates dosage adaptation in clinical practice as it provides a simple and
effective method to monitor MPA even in resource-constrained settings.</p></sec><sec sec-type="supplementary-material" id="section18-0963689720912925" specific-use="figshare"><title>Supplemental Material</title><supplementary-material content-type="local-data" id="suppl1-0963689720912925" position="float" orientation="portrait"><caption><title>Supplementary_file_1 - A Limited Sampling Strategy for Therapeutic Drug
Monitoring of Mycophenolate Mofetil for Prophylaxis of Acute
Graft-Versus-Host Disease in Allogeneic Stem Cell Transplantation</title></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Supplementary_file_1.rtf" position="float" orientation="portrait"><caption><p>Click here for additional data file.</p></caption></media><p>Supplementary_file_1 for A Limited Sampling Strategy for Therapeutic Drug
Monitoring of Mycophenolate Mofetil for Prophylaxis of Acute Graft-Versus-Host
Disease in Allogeneic Stem Cell Transplantation by Vikram Gota, Vaitashi
Purohit, Murari Gurjar, Lingaraj Nayak, Sachin Punatar, Anant Gokarn, Avinash
Bonda, Bhausaheb Bagal, Chakor Sunil Vora, Anand Patil, Manjunath Nookala and
Navin Khattry in Cell Transplantation</p></supplementary-material></sec></body><back><ack><title>Acknowledgments</title><p>The authors are grateful to the Tata Memorial Centre Research Administration Council
(TRAC) for extending financial support for this study. The authors also express
their gratitude to Dr Parsshava Mehta for proofreading the manuscript.</p></ack><fn-group><fn fn-type="other" id="fn1-0963689720912925"><p><bold>Ethical Approval:</bold> Ethical approval to report this study was obtained from Institutional Ethics
Committee-III (IEC-III Approval number 65) of Tata Memorial Centre, Navi Mumbai,
India.</p></fn><fn fn-type="other" id="fn2-0963689720912925"><p><bold>Statement of Human and Animal Rights:</bold> All procedures in this study were conducted in accordance with the Institutional
Ethics Committee&#8211;III&#8217;s (Approval number 65) approved protocols, Good Clinical
Practice guidelines and the Declaration of Helsinki.</p></fn><fn fn-type="other" id="fn3-0963689720912925"><p><bold>Statement of Informed Consent:</bold> Written informed consent was obtained from all the patients for their anonymized
information to be published in this article.</p></fn><fn fn-type="COI-statement" id="fn4-0963689720912925"><p><bold>Declaration of Conflicting Interests:</bold> The author(s) declared no potential conflicts of interest with respect to the
research, authorship, and/or publication of this article.</p></fn><fn fn-type="financial-disclosure" id="fn5-0963689720912925"><p><bold>Funding:</bold> The author(s) disclosed receipt of the following financial support for the
research, authorship, and/or publication of this article: The author(s) received
financial support from the Tata Memorial Centre Research Administration Council
(TRAC) for conducting and publishing this study.</p></fn><fn fn-type="other" id="fn6-0963689720912925"><p><bold>ORCID iD:</bold> Vikram Gota <inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10.1177_0963689720912925-img1.jpg"/>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://orcid.org/0000-0001-6348-6667">https://orcid.org/0000-0001-6348-6667</ext-link>
</p></fn><fn fn-type="supplementary-material" id="fn7-0963689720912925"><p><bold>Supplemental Material:</bold> Supplemental material for this article is available online.</p></fn></fn-group><ref-list><title>References</title><ref id="bibr1-0963689720912925"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vogelsang</surname><given-names>GB</given-names></name><name name-style="western"><surname>Arai</surname><given-names>S</given-names></name></person-group><article-title>Mycophenolate mofetil for the prevention and
treatment of graft-versus-host disease following stem cell transplantation:
preliminary findings</article-title>. <source>Bone Marrow
Transplant</source>.
<year>2001</year>;<volume>27</volume>(<issue>12</issue>):<fpage>1255</fpage>&#8211;<lpage>1262</lpage>.<pub-id pub-id-type="pmid">11548843</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/sj.bmt.1703076</pub-id></mixed-citation></ref><ref id="bibr2-0963689720912925"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Royer</surname><given-names>B</given-names></name><name name-style="western"><surname>Larosa</surname><given-names>F</given-names></name><name name-style="western"><surname>Legrand</surname><given-names>F</given-names></name><name name-style="western"><surname>Gerritsen-van Schieveen</surname><given-names>P</given-names></name><name name-style="western"><surname>B&#233;rard</surname><given-names>M</given-names></name><name name-style="western"><surname>Kantelip</surname><given-names>JP</given-names></name><name name-style="western"><surname>Deconinck</surname><given-names>E</given-names></name></person-group><article-title>Pharmacokinetics of mycophenolic acid
administered 3 times daily after hematopoietic stem cell transplantation
with reduced-intensity regimen</article-title>. <source>Biol Blood Marrow
Transplant</source>.
<year>2009</year>;<volume>15</volume>(<issue>9</issue>):<fpage>1134</fpage>&#8211;<lpage>1139</lpage>.<pub-id pub-id-type="pmid">19660728</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbmt.2009.04.011</pub-id></mixed-citation></ref><ref id="bibr3-0963689720912925"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sollinger</surname><given-names>HW</given-names></name><name name-style="western"><surname>Belzer</surname><given-names>FO</given-names></name><name name-style="western"><surname>Deierhoi</surname><given-names>MH</given-names></name><name name-style="western"><surname>Diethelm</surname><given-names>AG</given-names></name><name name-style="western"><surname>Gonwa</surname><given-names>TA</given-names></name><name name-style="western"><surname>Kauffman</surname><given-names>RS</given-names></name><name name-style="western"><surname>Klintmalm</surname><given-names>GB</given-names></name><name name-style="western"><surname>McDiarmid</surname><given-names>SV</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>J</given-names></name><name name-style="western"><surname>Rosenthal</surname><given-names>JT</given-names></name></person-group><article-title>Rs-61443 (mycophenolate mofetil). a multicenter
study for refractory kidney transplant rejection</article-title>.
<source>Ann Surg</source>.
<year>1992</year>;<volume>216</volume>(<issue>4</issue>):<fpage>513</fpage>&#8211;<lpage>518</lpage>;<pub-id pub-id-type="pmid">1417199</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/00000658-199210000-00014</pub-id><pub-id pub-id-type="pmcid">PMC1242662</pub-id></mixed-citation></ref><ref id="bibr4-0963689720912925"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sollinger</surname><given-names>HW</given-names></name><name name-style="western"><surname>Deierhoi</surname><given-names>MH</given-names></name><name name-style="western"><surname>Belzer</surname><given-names>FO</given-names></name><name name-style="western"><surname>Diethelm</surname><given-names>AG</given-names></name><name name-style="western"><surname>Kauffman</surname><given-names>RS</given-names></name></person-group><article-title>Rs-61443--a phase i clinical trial and pilot
rescue study</article-title>. <source>Transplantation</source>.
<year>1992</year>;<volume>53</volume>(<issue>2</issue>):<fpage>428</fpage>&#8211;<lpage>432</lpage>.<pub-id pub-id-type="pmid">1346731</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/00007890-199202010-00031</pub-id></mixed-citation></ref><ref id="bibr5-0963689720912925"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Halloran</surname><given-names>P</given-names></name><name name-style="western"><surname>Mathew</surname><given-names>T</given-names></name><name name-style="western"><surname>Tomlanovich</surname><given-names>S</given-names></name><name name-style="western"><surname>Groth</surname><given-names>C</given-names></name><name name-style="western"><surname>Hooftman</surname><given-names>L</given-names></name><name name-style="western"><surname>Barker</surname><given-names>C</given-names></name></person-group><article-title>Mycophenolate mofetil in renal allograft
recipients: a pooled efficacy analysis of three randomized, double-blind,
clinical studies in prevention of rejection. the international mycophenolate
mofetil renal transplant study groups</article-title>.
<source>Transplantation</source>.
<year>1997</year>;<volume>63</volume>(<issue>1</issue>):<fpage>39</fpage>&#8211;<lpage>47</lpage>.<pub-id pub-id-type="pmid">9000658</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/00007890-199701150-00008</pub-id></mixed-citation></ref><ref id="bibr6-0963689720912925"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pirsch</surname><given-names>JD</given-names></name><name name-style="western"><surname>Sollinger</surname><given-names>HW</given-names></name></person-group><article-title>Mycophenolate mofetil--clinical and experimental
experience</article-title>. <source>Ther Drug Monit</source>.
<year>1996</year>;<volume>18</volume>(<issue>4</issue>):<fpage>357</fpage>&#8211;<lpage>361</lpage>.<pub-id pub-id-type="pmid">8857550</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/00007691-199608000-00007</pub-id></mixed-citation></ref><ref id="bibr7-0963689720912925"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jain</surname><given-names>AB</given-names></name><name name-style="western"><surname>Hamad</surname><given-names>I</given-names></name><name name-style="western"><surname>Rakela</surname><given-names>J</given-names></name><name name-style="western"><surname>Dodson</surname><given-names>F</given-names></name><name name-style="western"><surname>Kramer</surname><given-names>D</given-names></name><name name-style="western"><surname>Demetris</surname><given-names>J</given-names></name><name name-style="western"><surname>McMichael</surname><given-names>J</given-names></name><name name-style="western"><surname>Starzl</surname><given-names>TE</given-names></name><name name-style="western"><surname>Fung</surname><given-names>JJ. A</given-names></name></person-group><article-title>prospective randomized trial of tacrolimus and prednisone versus
tacrolimus, prednisone, and mycophenolate mofetil in primary adult liver
transplant recipients: An interim report</article-title>.
<source>Transplantation</source>.
<year>1998</year>;<volume>66</volume>(<issue>10</issue>):<fpage>1395</fpage>&#8211;<lpage>1398</lpage>.<pub-id pub-id-type="pmid">9846530</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/00007890-199811270-00024</pub-id><pub-id pub-id-type="pmcid">PMC2952474</pub-id></mixed-citation></ref><ref id="bibr8-0963689720912925"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bornh&#228;user</surname><given-names>M</given-names></name><name name-style="western"><surname>Schuler</surname><given-names>U</given-names></name><name name-style="western"><surname>P&#246;rksen</surname><given-names>G</given-names></name><name name-style="western"><surname>Naumann</surname><given-names>R</given-names></name><name name-style="western"><surname>Geissler</surname><given-names>G</given-names></name><name name-style="western"><surname>Thiede</surname><given-names>C</given-names></name><name name-style="western"><surname>Schwerdtfeger</surname><given-names>R</given-names></name><name name-style="western"><surname>Ehninger</surname><given-names>G</given-names></name><name name-style="western"><surname>Thiede</surname><given-names>HM</given-names></name></person-group><article-title>Mycophenolate mofetil and cyclosporine as
graft-versus-host disease prophylaxis after allogeneic blood stem cell
transplantation</article-title>. <source>Transplantation</source>.
<year>1999</year>;<volume>67</volume>(<issue>4</issue>):<fpage>499</fpage>&#8211;<lpage>504</lpage>.<pub-id pub-id-type="pmid">10071016</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/00007890-199902270-00001</pub-id></mixed-citation></ref><ref id="bibr9-0963689720912925"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kobashigawa</surname><given-names>J</given-names></name><name name-style="western"><surname>Miller</surname><given-names>L</given-names></name><name name-style="western"><surname>Renlund</surname><given-names>D</given-names></name><name name-style="western"><surname>Mentzer</surname><given-names>R</given-names></name><name name-style="western"><surname>Alderman</surname><given-names>E</given-names></name><name name-style="western"><surname>Bourge</surname><given-names>R</given-names></name><name name-style="western"><surname>Costanzo</surname><given-names>M</given-names></name><name name-style="western"><surname>Eisen</surname><given-names>H</given-names></name><name name-style="western"><surname>Dureau</surname><given-names>G</given-names></name><name name-style="western"><surname>Ratkovec</surname><given-names>R</given-names></name><name name-style="western"><surname>Hummel</surname><given-names>M</given-names></name></person-group>, <etal>et al.</etal><article-title>A randomized active-controlled trial of mycophenolate mofetil in
heart transplant recipients mycophenolate mofetil
investigators</article-title>. <source>Transplantation</source>.
<year>1998</year>;<volume>66</volume>(<issue>4</issue>):<fpage>507</fpage>&#8211;<lpage>515</lpage>.<pub-id pub-id-type="pmid">9734496</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/00007890-199808270-00016</pub-id></mixed-citation></ref><ref id="bibr10-0963689720912925"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>D</given-names></name><name name-style="western"><surname>Renbarger</surname><given-names>JL</given-names></name><name name-style="western"><surname>Chow</surname><given-names>DS</given-names></name></person-group><article-title>Pharmacokinetic variability of mycophenolic acid
in pediatric and adult patients with hematopoietic stem cell
transplantation</article-title>. <source>J Clin Pharmacol</source>.
<year>2016</year>;<volume>56</volume>(<issue>11</issue>):<fpage>1378</fpage>&#8211;<lpage>1386</lpage>.<pub-id pub-id-type="pmid">27060685</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jcph.745</pub-id></mixed-citation></ref><ref id="bibr11-0963689720912925"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van Hest</surname><given-names>RM</given-names></name><name name-style="western"><surname>Doorduijn</surname><given-names>JK</given-names></name><name name-style="western"><surname>de Winter</surname><given-names>BC</given-names></name><name name-style="western"><surname>Cornelissen</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Vulto</surname><given-names>AG</given-names></name><name name-style="western"><surname>Oellerich</surname><given-names>M</given-names></name><name name-style="western"><surname>L&#246;wenberg</surname><given-names>B</given-names></name><name name-style="western"><surname>Mathot</surname><given-names>RA</given-names></name><name name-style="western"><surname>Armstrong</surname><given-names>VW</given-names></name><name name-style="western"><surname>van Gelder</surname><given-names>T</given-names></name></person-group><article-title>Pharmacokinetics of mycophenolate mofetil in
hematopoietic stem cell transplant recipients</article-title>. <source>Ther
Drug Monit</source>.
<year>2007</year>;<volume>29</volume>(<issue>3</issue>):<fpage>353</fpage>&#8211;<lpage>360</lpage>.<pub-id pub-id-type="pmid">17529894</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/FTD.0b013e31805d8816</pub-id></mixed-citation></ref><ref id="bibr12-0963689720912925"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jacobson</surname><given-names>P</given-names></name><name name-style="western"><surname>Green</surname><given-names>K</given-names></name><name name-style="western"><surname>Rogosheske</surname><given-names>J</given-names></name><name name-style="western"><surname>Brunstein</surname><given-names>C</given-names></name><name name-style="western"><surname>Ebeling</surname><given-names>B</given-names></name><name name-style="western"><surname>DeFor</surname><given-names>T</given-names></name><name name-style="western"><surname>McGlave</surname><given-names>P</given-names></name><name name-style="western"><surname>Weisdorf</surname><given-names>D</given-names></name></person-group><article-title>Highly variable mycophenolate mofetil
bioavailability following nonmyeloablative hematopoietic cell
transplantation</article-title>. <source>J Clin Pharmacol</source>.
<year>2007</year>;<volume>47</volume>(<issue>1</issue>):<fpage>6</fpage>&#8211;<lpage>12</lpage>.<pub-id pub-id-type="pmid">17192496</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/0091270006295064</pub-id></mixed-citation></ref><ref id="bibr13-0963689720912925"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jacobson</surname><given-names>PA</given-names></name><name name-style="western"><surname>Huang</surname><given-names>J</given-names></name><name name-style="western"><surname>Wu</surname><given-names>J</given-names></name><name name-style="western"><surname>Kim</surname><given-names>M</given-names></name><name name-style="western"><surname>Logan</surname><given-names>B</given-names></name><name name-style="western"><surname>Alousi</surname><given-names>A</given-names></name><name name-style="western"><surname>Grimley</surname><given-names>M</given-names></name><name name-style="western"><surname>Bola&#241;os-Meade</surname><given-names>J</given-names></name><name name-style="western"><surname>Ho</surname><given-names>V</given-names></name><name name-style="western"><surname>Levine</surname><given-names>JE</given-names></name><name name-style="western"><surname>Weisdorf</surname><given-names>D</given-names></name></person-group><article-title>Mycophenolate pharmacokinetics and association
with response to acute graft-versus-host disease treatment from the blood
and marrow transplant clinical trials network</article-title>. <source>Biol
Blood Marrow Transplant</source>.
<year>2010</year>;<volume>16</volume>(<issue>3</issue>):<fpage>421</fpage>&#8211;<lpage>429</lpage>.<pub-id pub-id-type="pmid">19925875</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbmt.2009.11.010</pub-id><pub-id pub-id-type="pmcid">PMC3104501</pub-id></mixed-citation></ref><ref id="bibr14-0963689720912925"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Knight</surname><given-names>SR</given-names></name><name name-style="western"><surname>Morris</surname><given-names>PJ</given-names></name></person-group><article-title>Does the evidence support the use of
mycophenolate mofetil therapeutic drug monitoring in clinical practice? a
systematic review</article-title>. <source>Transplantation</source>.
<year>2008</year>;<volume>85</volume>(<issue>12</issue>):<fpage>1675</fpage>&#8211;<lpage>1685</lpage>.<pub-id pub-id-type="pmid">18580456</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/TP.0b013e3181744199</pub-id></mixed-citation></ref><ref id="bibr15-0963689720912925"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Haentzschel</surname><given-names>I</given-names></name><name name-style="western"><surname>Freiberg-Richter</surname><given-names>J</given-names></name><name name-style="western"><surname>Platzbecker</surname><given-names>U</given-names></name><name name-style="western"><surname>Kiani</surname><given-names>A</given-names></name><name name-style="western"><surname>Schetelig</surname><given-names>J</given-names></name><name name-style="western"><surname>Illmer</surname><given-names>T</given-names></name><name name-style="western"><surname>Ehninger</surname><given-names>G</given-names></name><name name-style="western"><surname>Schleyer</surname><given-names>E</given-names></name><name name-style="western"><surname>Bornh&#228;user</surname><given-names>M</given-names></name></person-group><article-title>Targeting mycophenolate mofetil for
graft-versus-host disease prophylaxis after allogeneic blood stem cell
transplantation</article-title>. <source>Bone Marrow Transplant</source>.
<year>2008</year>;<volume>42</volume>(<issue>2</issue>):<fpage>113</fpage>&#8211;<lpage>120</lpage>.<pub-id pub-id-type="pmid">18362900</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/bmt.2008.85</pub-id></mixed-citation></ref><ref id="bibr16-0963689720912925"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Minagawa</surname><given-names>K</given-names></name><name name-style="western"><surname>Yamamori</surname><given-names>M</given-names></name><name name-style="western"><surname>Katayama</surname><given-names>Y</given-names></name><name name-style="western"><surname>Matsui</surname><given-names>T</given-names></name></person-group><article-title>Mycophenolate mofetil: Fully utilizing its
benefits for gvhd prophylaxis</article-title>. <source>Int J
Hematol</source>.
<year>2012</year>;<volume>96</volume>(<issue>1</issue>):<fpage>10</fpage>&#8211;<lpage>25</lpage>.<pub-id pub-id-type="pmid">22592321</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12185-012-1086-x</pub-id></mixed-citation></ref><ref id="bibr17-0963689720912925"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shaw</surname><given-names>LM</given-names></name><name name-style="western"><surname>Figurski</surname><given-names>M</given-names></name><name name-style="western"><surname>Milone</surname><given-names>MC</given-names></name><name name-style="western"><surname>Trofe</surname><given-names>J</given-names></name><name name-style="western"><surname>Bloom</surname><given-names>RD</given-names></name></person-group><article-title>Therapeutic drug monitoring of mycophenolic
acid</article-title>. <source>Clin J Am Soc Nephrol</source>.
<year>2007</year>;<volume>2</volume>(<issue>5</issue>):<fpage>1062</fpage>&#8211;<lpage>1072</lpage>.<pub-id pub-id-type="pmid">17702714</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2215/CJN.03861106</pub-id></mixed-citation></ref><ref id="bibr18-0963689720912925"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bullingham</surname><given-names>R</given-names></name><name name-style="western"><surname>Monroe</surname><given-names>S</given-names></name><name name-style="western"><surname>Nicholls</surname><given-names>A</given-names></name><name name-style="western"><surname>Hale</surname><given-names>M</given-names></name></person-group><article-title>Pharmacokinetics and bioavailability of
mycophenolate mofetil in healthy subjects after single-dose oral and
intravenous administration</article-title>. <source>J Clin
Pharmacol</source>.
<year>1996</year>;<volume>36</volume>(<issue>4</issue>):<fpage>315</fpage>&#8211;<lpage>324</lpage>.<pub-id pub-id-type="pmid">8728345</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/j.1552-4604.1996.tb04207.x</pub-id></mixed-citation></ref><ref id="bibr19-0963689720912925"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bullingham</surname><given-names>RE</given-names></name><name name-style="western"><surname>Nicholls</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Kamm</surname><given-names>BR</given-names></name></person-group><article-title>Clinical pharmacokinetics of mycophenolate
mofetil</article-title>. <source>Clin Pharmacokinet</source>.
<year>1998</year>;<volume>34</volume>(<issue>6</issue>):<fpage>429</fpage>&#8211;<lpage>455</lpage>.<pub-id pub-id-type="pmid">9646007</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2165/00003088-199834060-00002</pub-id></mixed-citation></ref><ref id="bibr20-0963689720912925"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kennedy</surname><given-names>GA</given-names></name><name name-style="western"><surname>Butler</surname><given-names>J</given-names></name><name name-style="western"><surname>Western</surname><given-names>R</given-names></name><name name-style="western"><surname>Morton</surname><given-names>J</given-names></name><name name-style="western"><surname>Durrant</surname><given-names>S</given-names></name><name name-style="western"><surname>Hill</surname><given-names>GR</given-names></name></person-group><article-title>Combination antithymocyte globulin and soluble
tnfalpha inhibitor (etanercept) +/- mycophenolate mofetil for treatment of
steroid refractory acute graft-versus-host disease</article-title>.
<source>Bone Marrow Transplant</source>.
<year>2006</year>;<volume>37</volume>(<issue>12</issue>):<fpage>1143</fpage>&#8211;<lpage>1147</lpage>.<pub-id pub-id-type="pmid">16699531</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/sj.bmt.1705380</pub-id></mixed-citation></ref><ref id="bibr21-0963689720912925"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mookerjee</surname><given-names>B</given-names></name><name name-style="western"><surname>Altomonte</surname><given-names>V</given-names></name><name name-style="western"><surname>Vogelsang</surname><given-names>G</given-names></name></person-group><article-title>Salvage therapy for refractory chronic
graft-versus-host disease with mycophenolate mofetil and
tacrolimus</article-title>. <source>Bone Marrow Transplant</source>.
<year>1999</year>;<volume>24</volume>(<issue>5</issue>):<fpage>517</fpage>&#8211;<lpage>520</lpage>.<pub-id pub-id-type="pmid">10482936</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/sj.bmt.1701936</pub-id></mixed-citation></ref><ref id="bibr22-0963689720912925"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McSweeney</surname><given-names>PA</given-names></name><name name-style="western"><surname>Niederwieser</surname><given-names>D</given-names></name><name name-style="western"><surname>Shizuru</surname><given-names>JA</given-names></name><name name-style="western"><surname>Sandmaier</surname><given-names>BM</given-names></name><name name-style="western"><surname>Molina</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Maloney</surname><given-names>DG</given-names></name><name name-style="western"><surname>Chauncey</surname><given-names>TR</given-names></name><name name-style="western"><surname>Gooley</surname><given-names>TA</given-names></name><name name-style="western"><surname>Hegenbart</surname><given-names>U</given-names></name><name name-style="western"><surname>Nash</surname><given-names>RA</given-names></name><name name-style="western"><surname>Radich</surname><given-names>J</given-names></name></person-group>, <etal>et al.</etal><article-title>Hematopoietic cell transplantation in older patients with
hematologic malignancies: replacing high-dose cytotoxic therapy with
graft-versus-tumor effects</article-title>. <source>Blood</source>.
<year>2001</year>;<volume>97</volume>(<issue>11</issue>):<fpage>3390</fpage>&#8211;<lpage>3400</lpage>.<pub-id pub-id-type="pmid">11369628</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1182/blood.v97.11.3390</pub-id></mixed-citation></ref><ref id="bibr23-0963689720912925"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>C</given-names></name><name name-style="western"><surname>Seidel</surname><given-names>K</given-names></name><name name-style="western"><surname>Nash</surname><given-names>RA</given-names></name><name name-style="western"><surname>Deeg</surname><given-names>HJ</given-names></name><name name-style="western"><surname>Sandmaier</surname><given-names>BM</given-names></name><name name-style="western"><surname>Barsoukov</surname><given-names>A</given-names></name><name name-style="western"><surname>Santos</surname><given-names>E</given-names></name><name name-style="western"><surname>Storb</surname><given-names>R</given-names></name></person-group><article-title>Synergism between mycophenolate mofetil and
cyclosporine in preventing graft-versus-host disease among lethally
irradiated dogs given dla-nonidentical unrelated marrow
grafts</article-title>. <source>Blood</source>.
<year>1998</year>;<volume>91</volume>(<issue>7</issue>):<fpage>2581</fpage>&#8211;<lpage>2587</lpage>.<pub-id pub-id-type="pmid">9516160</pub-id></mixed-citation></ref><ref id="bibr24-0963689720912925"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ng</surname><given-names>J</given-names></name><name name-style="western"><surname>Rogosheske</surname><given-names>J</given-names></name><name name-style="western"><surname>Barker</surname><given-names>J</given-names></name><name name-style="western"><surname>Weisdorf</surname><given-names>D</given-names></name><name name-style="western"><surname>Jacobson</surname><given-names>PA</given-names></name></person-group><article-title>A limited sampling model for estimation of total
and unbound mycophenolic acid (mpa) area under the curve (auc) in
hematopoietic cell transplantation (hct)</article-title>. <source>Ther Drug
Monit</source>.
<year>2006</year>;<volume>28</volume>(<issue>3</issue>):<fpage>394</fpage>&#8211;<lpage>401</lpage>.<pub-id pub-id-type="pmid">16778725</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/01.ftd.0000211821.73231.8a</pub-id></mixed-citation></ref><ref id="bibr25-0963689720912925"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Borrows</surname><given-names>R</given-names></name><name name-style="western"><surname>Chusney</surname><given-names>G</given-names></name><name name-style="western"><surname>Loucaidou</surname><given-names>M</given-names></name><name name-style="western"><surname>James</surname><given-names>A</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J</given-names></name><name name-style="western"><surname>Tromp</surname><given-names>JV</given-names></name><name name-style="western"><surname>Owen</surname><given-names>J</given-names></name><name name-style="western"><surname>Cairns</surname><given-names>T</given-names></name><name name-style="western"><surname>Griffith</surname><given-names>M</given-names></name><name name-style="western"><surname>Hakim</surname><given-names>N</given-names></name><name name-style="western"><surname>McLean</surname><given-names>A</given-names></name></person-group>, <etal>et al.</etal><article-title>Mycophenolic acid 12-h trough level monitoring in renal
transplantation: association with acute rejection and
toxicity</article-title>. <source>Am J Transplant</source>.
<year>2006</year>;<volume>6</volume>(<issue>1</issue>):<fpage>121</fpage>&#8211;<lpage>128</lpage>.<pub-id pub-id-type="pmid">16433766</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1600-6143.2005.01151.x</pub-id></mixed-citation></ref><ref id="bibr26-0963689720912925"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hiwarkar</surname><given-names>P</given-names></name><name name-style="western"><surname>Shaw</surname><given-names>BE</given-names></name><name name-style="western"><surname>Tredger</surname><given-names>JM</given-names></name><name name-style="western"><surname>Brown</surname><given-names>NW</given-names></name><name name-style="western"><surname>Kulkarni</surname><given-names>S</given-names></name><name name-style="western"><surname>Saso</surname><given-names>R</given-names></name><name name-style="western"><surname>Evans</surname><given-names>S</given-names></name><name name-style="western"><surname>Treleaven</surname><given-names>J</given-names></name><name name-style="western"><surname>Davies</surname><given-names>FE</given-names></name><name name-style="western"><surname>Ethell</surname><given-names>ME</given-names></name><name name-style="western"><surname>Morgan</surname><given-names>GJ</given-names></name></person-group>, <etal>et al.</etal><article-title>Mycophenolic acid trough level monitoring: Relevance in acute and
chronic graft versus host disease and its relation with
albumin</article-title>. <source>Clin Transplant</source>.
<year>2011</year>;<volume>25</volume>(<issue>2</issue>):<fpage>222</fpage>&#8211;<lpage>227</lpage>.<pub-id pub-id-type="pmid">20201951</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1399-0012.2010.01226.x</pub-id></mixed-citation></ref><ref id="bibr27-0963689720912925"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>de Winter</surname><given-names>BC</given-names></name><name name-style="western"><surname>Math&#244;t</surname><given-names>RA</given-names></name><name name-style="western"><surname>van Hest</surname><given-names>RM</given-names></name><name name-style="western"><surname>van Gelder</surname><given-names>T</given-names></name></person-group><article-title>Therapeutic drug monitoring of mycophenolic
acid: does it improve patient outcome?</article-title><source>Expert Opin Drug Metab Toxicol</source>.
<year>2007</year>;<volume>3</volume>(<issue>2</issue>):<fpage>251</fpage>&#8211;<lpage>261</lpage>.<pub-id pub-id-type="pmid">17428154</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1517/17425255.3.2.251</pub-id></mixed-citation></ref><ref id="bibr28-0963689720912925"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Noreikait&#279;</surname><given-names>A</given-names></name><name name-style="western"><surname>Saint-Marcoux</surname><given-names>F</given-names></name><name name-style="western"><surname>Marquet</surname><given-names>P</given-names></name><name name-style="western"><surname>Kadu&#353;evi&#269;ius</surname><given-names>E</given-names></name><name name-style="western"><surname>Stankevi&#269;ius</surname><given-names>E</given-names></name></person-group><article-title>Influence of cyclosporine and everolimus on the
main mycophenolate mofetil pharmacokinetic parameters: cross-sectional
study</article-title>. <source>Medicine (Baltimore)</source>.
<year>2017</year>;<volume>96</volume>(<issue>13</issue>):
<fpage>e6469</fpage>.<pub-id pub-id-type="pmid">28353583</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/MD.0000000000006469</pub-id><pub-id pub-id-type="pmcid">PMC5380267</pub-id></mixed-citation></ref><ref id="bibr29-0963689720912925"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yau</surname><given-names>WP</given-names></name><name name-style="western"><surname>Vathsala</surname><given-names>A</given-names></name><name name-style="western"><surname>Lou</surname><given-names>HX</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>S</given-names></name><name name-style="western"><surname>Chan</surname><given-names>E</given-names></name></person-group><article-title>Mechanism-based enterohepatic circulation model
of mycophenolic acid and its glucuronide metabolite: assessment of impact of
cyclosporine dose in asian renal transplant patients</article-title>.
<source>J Clin Pharmacol</source>.
<year>2009</year>;<volume>49</volume>(<issue>6</issue>):<fpage>684</fpage>&#8211;<lpage>699</lpage>.<pub-id pub-id-type="pmid">19386625</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/0091270009332813</pub-id></mixed-citation></ref><ref id="bibr30-0963689720912925"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Naito</surname><given-names>T</given-names></name><name name-style="western"><surname>Mino</surname><given-names>Y</given-names></name><name name-style="western"><surname>Otsuka</surname><given-names>A</given-names></name><name name-style="western"><surname>Ushiyama</surname><given-names>T</given-names></name><name name-style="western"><surname>Ito</surname><given-names>T</given-names></name><name name-style="western"><surname>Ozono</surname><given-names>S</given-names></name><name name-style="western"><surname>Kagawa</surname><given-names>Y</given-names></name><name name-style="western"><surname>Kawakami</surname><given-names>J</given-names></name></person-group><article-title>Impact of calcineurin inhibitors on urinary
excretion of mycophenolic acid and its glucuronide in kidney transplant
recipients</article-title>. <source>J Clin Pharmacol</source>.
<year>2009</year>;<volume>49</volume>(<issue>6</issue>):<fpage>710</fpage>&#8211;<lpage>718</lpage>.<pub-id pub-id-type="pmid">19451405</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/0091270009335003</pub-id></mixed-citation></ref><ref id="bibr31-0963689720912925"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jacobson</surname><given-names>P</given-names></name><name name-style="western"><surname>Rogosheske</surname><given-names>J</given-names></name><name name-style="western"><surname>Barker</surname><given-names>JN</given-names></name><name name-style="western"><surname>Green</surname><given-names>K</given-names></name><name name-style="western"><surname>Ng</surname><given-names>J</given-names></name><name name-style="western"><surname>Weisdorf</surname><given-names>D</given-names></name><name name-style="western"><surname>Tan</surname><given-names>Y</given-names></name><name name-style="western"><surname>Long</surname><given-names>J</given-names></name><name name-style="western"><surname>Remmel</surname><given-names>R</given-names></name><name name-style="western"><surname>Sawchuk</surname><given-names>R</given-names></name></person-group>, <etal>et al.</etal><year>2005</year><article-title>Relationship of mycophenolic acid exposure to
clinical outcome after hematopoietic cell transplantation</article-title>.
<source>Clin Pharmacol Ther</source>.
<volume>78</volume>(<issue>5</issue>):<fpage>486</fpage>&#8211;<lpage>500</lpage>.<pub-id pub-id-type="pmid">16321615</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.clpt.2005.08.009</pub-id></mixed-citation></ref><ref id="bibr32-0963689720912925"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ensom</surname><given-names>MH</given-names></name><name name-style="western"><surname>Partovi</surname><given-names>N</given-names></name><name name-style="western"><surname>Decarie</surname><given-names>D</given-names></name><name name-style="western"><surname>Ignaszewski</surname><given-names>AP</given-names></name><name name-style="western"><surname>Fradet</surname><given-names>GJ</given-names></name><name name-style="western"><surname>Levy</surname><given-names>RD</given-names></name></person-group><article-title>Mycophenolate pharmacokinetics in early period
following lung or heart transplantation</article-title>. <source>Ann
Pharmacother</source>.
<year>2003</year>;<volume>37</volume>(<issue>12</issue>):<fpage>1761</fpage>&#8211;<lpage>1767</lpage>.<pub-id pub-id-type="pmid">14632536</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1345/aph.1D099</pub-id></mixed-citation></ref><ref id="bibr33-0963689720912925"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Windreich</surname><given-names>RM</given-names></name><name name-style="western"><surname>Goyal</surname><given-names>RK</given-names></name><name name-style="western"><surname>Joshi</surname><given-names>R</given-names></name><name name-style="western"><surname>Kenkre</surname><given-names>TS</given-names></name><name name-style="western"><surname>Howrie</surname><given-names>D</given-names></name><name name-style="western"><surname>Venkataramanan</surname><given-names>R</given-names></name></person-group><article-title>A pilot study of continuous infusion of
mycophenolate mofetil for prophylaxis of graft-versus-host-disease in
pediatric patients</article-title>. <source>Biol Blood Marrow
Transplant</source>.
<year>2016</year>;<volume>22</volume>(<issue>4</issue>):<fpage>682</fpage>&#8211;<lpage>689</lpage>.<pub-id pub-id-type="pmid">26740371</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbmt.2015.12.013</pub-id></mixed-citation></ref><ref id="bibr34-0963689720912925"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McCune</surname><given-names>JS</given-names></name><name name-style="western"><surname>Jacobson</surname><given-names>P</given-names></name><name name-style="western"><surname>Wiseman</surname><given-names>A</given-names></name><name name-style="western"><surname>Militano</surname><given-names>O</given-names></name></person-group><article-title>Optimizing drug therapy in pediatric sct: focus
on pharmacokinetics</article-title>. <source>Bone Marrow
Transplant</source>.
<year>2015</year>;<volume>50</volume>(<issue>2</issue>):<fpage>165</fpage>&#8211;<lpage>172</lpage>.<pub-id pub-id-type="pmid">25347008</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/bmt.2014.235</pub-id><pub-id pub-id-type="pmcid">PMC5996991</pub-id></mixed-citation></ref><ref id="bibr35-0963689720912925"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Filler</surname><given-names>G</given-names></name><name name-style="western"><surname>Feber</surname><given-names>J</given-names></name><name name-style="western"><surname>Lepage</surname><given-names>N</given-names></name><name name-style="western"><surname>Weiler</surname><given-names>G</given-names></name><name name-style="western"><surname>Mai</surname><given-names>I</given-names></name></person-group><article-title>Universal approach to pharmacokinetic monitoring
of immunosuppressive agents in children</article-title>. <source>Pediatr
Transplant</source>.
<year>2002</year>;<volume>6</volume>(<issue>5</issue>):<fpage>411</fpage>&#8211;<lpage>418</lpage>.<pub-id pub-id-type="pmid">12390429</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1034/j.1399-3046.2002.02039.x</pub-id></mixed-citation></ref><ref id="bibr36-0963689720912925"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cai</surname><given-names>W</given-names></name><name name-style="western"><surname>Cai</surname><given-names>Q</given-names></name><name name-style="western"><surname>Xiong</surname><given-names>N</given-names></name><name name-style="western"><surname>Qin</surname><given-names>Y</given-names></name><name name-style="western"><surname>Lai</surname><given-names>L</given-names></name><name name-style="western"><surname>Sun</surname><given-names>X</given-names></name><name name-style="western"><surname>Hu</surname><given-names>Y</given-names></name></person-group><article-title>Limited sampling strategy for estimating
mycophenolic acid exposure on day 7 post-transplant for two mycophenolate
mofetil formulations derived from 20 chinese renal transplant
recipients</article-title>. <source>Transplant Proc</source>.
<year>2018</year>;<volume>50</volume>(<issue>5</issue>):<fpage>1298</fpage>&#8211;<lpage>1304</lpage>.<pub-id pub-id-type="pmid">29735215</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.transproceed.2018.02.068</pub-id></mixed-citation></ref><ref id="bibr37-0963689720912925"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brooks</surname><given-names>EK</given-names></name><name name-style="western"><surname>Tett</surname><given-names>SE</given-names></name><name name-style="western"><surname>Isbel</surname><given-names>NM</given-names></name><name name-style="western"><surname>McWhinney</surname><given-names>B</given-names></name><name name-style="western"><surname>Staatz</surname><given-names>CE</given-names></name></person-group><article-title>Evaluation of multiple linear regression-based
limited sampling strategies for enteric-coated mycophenolate sodium in adult
kidney transplant recipients</article-title>. <source>Ther Drug
Monit</source>.
<year>2018</year>;<volume>40</volume>(<issue>2</issue>):<fpage>195</fpage>&#8211;<lpage>201</lpage>.<pub-id pub-id-type="pmid">29461443</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/FTD.0000000000000486</pub-id></mixed-citation></ref><ref id="bibr38-0963689720912925"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Le Guellec</surname><given-names>C</given-names></name><name name-style="western"><surname>B&#252;chler</surname><given-names>M</given-names></name><name name-style="western"><surname>Giraudeau</surname><given-names>B</given-names></name><name name-style="western"><surname>Le Meur</surname><given-names>Y</given-names></name><name name-style="western"><surname>Gakou&#233;</surname><given-names>JE</given-names></name><name name-style="western"><surname>Lebranchu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Marquet</surname><given-names>P</given-names></name><name name-style="western"><surname>Paintaud</surname><given-names>G</given-names></name></person-group><article-title>Simultaneous estimation of cyclosporin and
mycophenolic acid areas under the curve in stable renal transplant patients
using a limited sampling strategy</article-title>. <source>Eur J Clin
Pharmacol</source>.
<year>2002</year>;<volume>57</volume>(<issue>11</issue>):<fpage>805</fpage>&#8211;<lpage>811</lpage>.<pub-id pub-id-type="pmid">11868803</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00228-001-0389-2</pub-id></mixed-citation></ref><ref id="bibr39-0963689720912925"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Willis</surname><given-names>C</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>PJ</given-names></name><name name-style="western"><surname>Salm</surname><given-names>P</given-names></name><name name-style="western"><surname>Tett</surname><given-names>SE</given-names></name><name name-style="western"><surname>Pillans</surname><given-names>PI</given-names></name></person-group><article-title>Evaluation of limited sampling strategies for
estimation of 12-hour mycophenolic acid area under the plasma
concentration-time curve in adult renal transplant patients</article-title>.
<source>Ther Drug Monit</source>.
<year>2000</year>;<volume>22</volume>(<issue>5</issue>):<fpage>549</fpage>&#8211;<lpage>554</lpage>.<pub-id pub-id-type="pmid">11034260</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/00007691-200010000-00008</pub-id></mixed-citation></ref><ref id="bibr40-0963689720912925"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mudge</surname><given-names>DW</given-names></name><name name-style="western"><surname>Atcheson</surname><given-names>BA</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>PJ</given-names></name><name name-style="western"><surname>Pillans</surname><given-names>PI</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>DW</given-names></name></person-group><article-title>Severe toxicity associated with a markedly
elevated mycophenolic acid free fraction in a renal transplant
recipient</article-title>. <source>Ther Drug Monit</source>.
<year>2004</year>;<volume>26</volume>(<issue>4</issue>):<fpage>453</fpage>&#8211;<lpage>455</lpage>.<pub-id pub-id-type="pmid">15257077</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/00007691-200408000-00017</pub-id></mixed-citation></ref><ref id="bibr41-0963689720912925"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jeong</surname><given-names>H</given-names></name><name name-style="western"><surname>Kaplan</surname><given-names>B</given-names></name></person-group><article-title>Therapeutic monitoring of mycophenolate
mofetil</article-title>. <source>Clin J Am Soc Nephrol</source>.
<year>2007</year>;<volume>2</volume>(<issue>1</issue>):<fpage>184</fpage>&#8211;<lpage>191</lpage>.<pub-id pub-id-type="pmid">17699403</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2215/CJN.02860806</pub-id></mixed-citation></ref><ref id="bibr42-0963689720912925"><label>42</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arns</surname><given-names>W</given-names></name></person-group><article-title>Noninfectious gastrointestinal (gi)
complications of mycophenolic acid therapy: a consequence of local gi
toxicity?</article-title><source>Transplant Proc</source>.
<year>2007</year>;<volume>39</volume>(<issue>1</issue>):<fpage>88</fpage>&#8211;<lpage>93</lpage>.<pub-id pub-id-type="pmid">17275481</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.transproceed.2006.10.189</pub-id></mixed-citation></ref><ref id="bibr43-0963689720912925"><label>43</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hesselink</surname><given-names>DA</given-names></name><name name-style="western"><surname>van Hest</surname><given-names>RM</given-names></name><name name-style="western"><surname>Mathot</surname><given-names>RA</given-names></name><name name-style="western"><surname>Bonthuis</surname><given-names>F</given-names></name><name name-style="western"><surname>Weimar</surname><given-names>W</given-names></name><name name-style="western"><surname>de Bruin</surname><given-names>RW</given-names></name><name name-style="western"><surname>van Gelder</surname><given-names>T</given-names></name></person-group><article-title>Cyclosporine interacts with mycophenolic acid by
inhibiting the multidrug resistance-associated protein 2</article-title>.
<source>Am J Transplant</source>.
<year>2005</year>;<volume>5</volume>(<issue>5</issue>):<fpage>987</fpage>&#8211;<lpage>994</lpage>.<pub-id pub-id-type="pmid">15816878</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1046/j.1600-6143.2005.00779.x</pub-id></mixed-citation></ref><ref id="bibr44-0963689720912925"><label>44</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Westley</surname><given-names>IS</given-names></name><name name-style="western"><surname>Brogan</surname><given-names>LR</given-names></name><name name-style="western"><surname>Morris</surname><given-names>RG</given-names></name><name name-style="western"><surname>Evans</surname><given-names>AM</given-names></name><name name-style="western"><surname>Sallustio</surname><given-names>BC</given-names></name></person-group><article-title>Role of mrp2 in the hepatic disposition of
mycophenolic acid and its glucuronide metabolites: effect of
cyclosporine</article-title>. <source>Drug Metab Dispos</source>.
<year>2006</year>;<volume>34</volume>(<issue>2</issue>):<fpage>261</fpage>&#8211;<lpage>266</lpage>.<pub-id pub-id-type="pmid">16272406</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1124/dmd.105.006122</pub-id></mixed-citation></ref><ref id="bibr45-0963689720912925"><label>45</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kobayashi</surname><given-names>M</given-names></name><name name-style="western"><surname>Saitoh</surname><given-names>H</given-names></name><name name-style="western"><surname>Tadano</surname><given-names>K</given-names></name><name name-style="western"><surname>Takahashi</surname><given-names>Y</given-names></name><name name-style="western"><surname>Hirano</surname><given-names>T</given-names></name></person-group><article-title>Cyclosporin a, but not tacrolimus, inhibits the
biliary excretion of mycophenolic acid glucuronide possibly mediated by
multidrug resistance-associated protein 2 in rats</article-title>. <source>J
Pharmacol Exp Ther</source>.
<year>2004</year>;<volume>309</volume>(<issue>3</issue>):<fpage>1029</fpage>&#8211;<lpage>1035</lpage>.<pub-id pub-id-type="pmid">14978191</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1124/jpet.103.063073</pub-id></mixed-citation></ref><ref id="bibr46-0963689720912925"><label>46</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Berger</surname><given-names>I</given-names></name><name name-style="western"><surname>Haubrich</surname><given-names>K</given-names></name><name name-style="western"><surname>Ensom</surname><given-names>MHH</given-names></name><name name-style="western"><surname>Carr</surname><given-names>R</given-names></name></person-group><article-title>Relationship of limited sampling strategy and
adverse effects of mycophenolate mofetil in pediatric renal transplant
patients</article-title>. <source>Pediatr Transplant</source>.
<year>2019</year>;<volume>23</volume>(<issue>2</issue>):<fpage>e13355</fpage>.<pub-id pub-id-type="pmid">30689262</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/petr.13355</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>